Movano Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2021. The supplied filing is for Movano Inc., not Corvex, Inc. Amounts below are in U.S. dollars; financial statement amounts are generally in millions unless noted.
Business context and reporting period
Movano is a development-stage health technology company developing a radio-frequency platform and a planned wearable intended to measure glucose, blood pressure and heart rate. It had generated no revenue since inception and expected no revenue in the foreseeable future. The filing describes a working prototype but says substantial development and testing remain.
Key financial metrics
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $3.183 | $2.322 | $5.125 | $3.823 |
| General and administrative expense | $1.863 | $0.413 | $3.187 | $0.931 |
| Total operating expenses / operating loss | $5.046 | $2.735 | $8.312 | $4.754 |
| Net loss | $4.687 | $2.739 | $10.295 | $4.764 |
| Net loss per share, basic and diluted | $0.15 | $1.75 | $0.64 | $3.34 |
| Cash used in operating activities | Not separately stated | Not separately stated | $7.772 | $4.453 |
Loss per share is shown as a loss in the financial statements. No revenue or gross margin was reported; operating margins are not meaningful for this pre-revenue business.
- Liquidity at June 30, 2021: Cash and cash equivalents of $29.305 million plus short-term investments of $13.402 million, totaling $42.707 million. Current assets were $44.659 million; current liabilities were $1.751 million.
- Debt and liabilities: Convertible notes and accrued interest were converted into common stock in the IPO; no convertible-note balance remained at quarter-end. The PPP loan was fully forgiven in May 2021. Total liabilities were $2.164 million, including a $0.370 million early-exercised stock-option liability.
- Cash flows, six months: Investing activities used $13.728 million, primarily for short-term investments. Financing activities provided $45.095 million, primarily from the IPO. Cash and cash equivalents increased by $23.595 million.
Material changes versus the prior comparable period
- Q2 operating expenses rose $2.311 million year over year; R&D increased $0.861 million and G&A increased $1.450 million. Management attributed the increases primarily to company growth and activity.
- Six-month net loss increased to $10.295 million from $4.764 million, reflecting higher operating costs and $1.581 million of expense from changes in warrant fair value, along with convertible-note interest expense.
- Q2 net loss included a $0.351 million gain from PPP loan forgiveness. Six-month results also included the warrant fair-value expense and $0.883 million of interest expense.
- The March 2021 IPO raised capital, converted preferred stock and convertible notes into common shares, and moved the company from a deficit to $42.970 million of stockholders’ equity at June 30. Common shares outstanding rose to 32,772,060 from 6,393,069 at year-end 2020.
Outlook, risks and unusual items
- Management said the June 30 cash and short-term investments were expected to fund projected operating requirements for at least 12 months, but not to complete product development and commercialization. The company expects significant expenses and increasing losses and anticipates needing additional financing; no specific revenue, profit or launch guidance was provided.
- Key execution risks include proving the wearable’s measurement accuracy, completing development and clinical work, obtaining expected FDA 510(k) clearance and FCC compliance, and securing third-party design, manufacturing and distribution partners. The filing says the company had not established such partner relationships.
- Management said the COVID-19 impact remained uncertain. The company also cited competition, dependence on key personnel and consultants, intellectual-property protection, potential product liability, and access to capital as risks.
- Disclosure controls and procedures were reported ineffective as of June 30, 2021. Three material weaknesses involved segregation of duties, IT security and system access, and precision in financial-control design. Remediation efforts were underway, with no assurance they would be sufficient.
- No pending legal proceedings believed to have a material adverse effect were disclosed. The filing reported no off-balance-sheet arrangements and no material subsequent events.
Important facts for investors to verify
- Progress and independent validation of glucose and blood-pressure accuracy, clinical plans, and the expected regulatory pathway and timing.
- Actual operating cash burn, investment maturities, and whether the stated 12-month runway remains adequate as development spending increases.
- Future financing needs, potential dilution, and strategic-partner arrangements.
- Remediation of the three material weaknesses and the effectiveness of financial reporting controls in subsequent filings.
- Reconciliation of IPO proceeds: the notes cite $44.3 million of net proceeds, while the cash-flow statement and MD&A cite approximately $45.0 million. Also confirm share-count and potential dilution from outstanding options and warrants.